CIK 0001818794
- Large accelerated filer
Dyne Therapeutics, Inc.
Sign in to watch- Ticker
- DYN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 364883909
- Phone
- +1 781-786-8230
- Business address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $40,000
- in 1 filing
- Open-market sales, last 90 days
- $421,679
- in 7 filings, $422K under 10b5-1 plans
Net −$381,679. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-09-21 | Forbion Capital Fund IV Cooperatief U.A. 10% owner | Conversion · Series B Preferred Stock | −5,336,179 | 0 | ||
| 2020-09-21 | CureDuchenne Ventures, LLC 10% owner | Conversion | +602,972 | 602,972 | ||
| 2020-09-21 | CureDuchenne Ventures, LLC 10% owner | Conversion · Series A Preferred Stock | −2,000,000 | 0 | ||
| 2020-09-21 | Klein Lawrence Otto Director | Conversion | +10,725 | 10,725 | ||
| 2020-09-21 | Klein Lawrence Otto Director | Conversion · Series B Preferred Stock | −35,574 | 0 | ||
| 2020-09-21 | Stehman-Breen Catherine Director | Conversion | +10,725 | 115,713 | ||
| 2020-09-21 | Stehman-Breen Catherine Director | Conversion · Series B Preferred Stock | −35,574 | 0 | ||
| 2020-09-21 | Rhodes Jason P Director | Conversion | +6,029,726 | 8,140,130 | ||
| 2020-09-21 | Rhodes Jason P Director | Conversion | +1,608,785 | 1,608,785 | ||
| 2020-09-21 | Rhodes Jason P Director | Conversion · Series A Preferred Stock | −20,000,000 | 0 | ||
| 2020-09-21 | Rhodes Jason P Director | Conversion · Series B Preferred Stock | −5,336,179 | 0 | ||
| 2020-09-21 | Kersten Dirk Director | Conversion | +6,131,079 | 6,131,079 | ||
| 2020-09-21 | Kersten Dirk Director | Conversion · Series A Preferred Stock | −15,000,000 | 0 | ||
| 2020-09-21 | Kersten Dirk Director | Conversion · Series B Preferred Stock | −5,336,179 | 0 | ||
| 2020-09-21 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion | +1,608,785 | 1,608,785 | ||
| 2020-09-21 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion · Series B Preferred Stock | −5,336,179 | 0 | ||
| 2020-09-21 | Atlas Venture Fund XI, L.P. 10% owner | Conversion | +6,029,726 | 8,140,130 | ||
| 2020-09-21 | Atlas Venture Fund XI, L.P. 10% owner | Conversion | +1,608,785 | 1,608,785 | ||
| 2020-09-21 | Atlas Venture Fund XI, L.P. 10% owner | Conversion · Series A Preferred Stock | −20,000,000 | 0 | ||
| 2020-09-21 | Atlas Venture Fund XI, L.P. 10% owner | Conversion · Series B Preferred Stock | −5,336,179 | 0 |
Page 39 of 41 · 818 trades